@entity1138 and XXXX with concomitant radiotherapy in head and neck cancer.

@entity1 @entity213 @entity1138 @entity33 @entity1487
Forty-two previously untreated @entity1 with predominantly stage IV (35) head and @entity213 were treated preoperatively with @entity1138 and @entity1487 and concomitant radiotherapy with 5,000 to 6,000 rad using a split-course technique. Toxic reactions were acceptable. Five @entity1 developed severe @entity33 . The white blood cell count fell to 1,500/cu mm in two @entity1 ; the platelet count fell to 100,000/cu mm in three. Other complications occurred in three @entity1 . Eighty-six percent of @entity1 completed advised treatment. Complete response, assessed clinically and with histologic correlation, was 79% at primary sites and 69% at nodal sites. Twenty-seven @entity1 had a complete response (64%). Follow-up currently is between ten and 24 months. Though analysis of disease-free intervals and survival data is premature, the high complete response rates in this study are encouraging.
